Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Canada's OceanaGold Q2 gold output rises on higher production at Haile

Canada's OceanaGold Q2 gold output rises on higher production at Haile

ReutersReuters2026/08/05 21:23


Overview

  • Canada-based gold and copper miner's Q2 revenue rose, gold output up 7% from prior quarter

  • Net profit for Q2 was $222 mln, with strong free cash flow and no debt

  • Company returned $78 mln to shareholders via dividends and share buybacks in Q2


Outlook

  • Oceanagold maintains 2026 full-year gold production guidance at 520-590 koz

  • Company expects consolidated AISC to be near upper end of $1,750-$1,900/oz guidance range

  • Oceanagold forecasts higher gold production and lower AISC in H2 2026


Result Drivers

  • HIGHER GOLD PRODUCTION - Co said gold output rose 7% from prior quarter, driven by increased production at Haile

  • PRODUCTION WEIGHTED TO END OF QUARTER - Revenue reflected gold sales weighted towards the end of the quarter as production increased at Haile

  • HIGHER COSTS - Co said AISC rose due to labor cost inflation, continued investment in maintenance and reliability, unhedged energy costs and lower silver by-product credits


Company press release: ID:nPn9qWggZa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$647 mln

$767 mln (1 Analyst)

Q2 Net Income

$222 mln

Q2 Operating Cash Flow

$314 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the gold peer group is "buy"

  • Wall Street's median 12-month price target for OceanaGold Corp is C$56.00, about 58.8% above its August 4 closing price of C$35.27

  • The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 7 three months ago


Reuters Recommended Reads

  • Aug 4 - SSR Mining Q2 adjusted EPS misses analyst expectations

  • Aug 4 - Mexico's Fresnillo H1 revenue jumps on higher precious metal prices; raises dividend

  • Aug 4 - Hecla Mining Q2 revenue falls sequentially on lower metal prices


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well